Ferric citrate
- Generic Name
- Ferric citrate
- Brand Names
- Auryxia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H32Fe4O31
- CAS Number
- -
- Unique Ingredient Identifier
- Q91187K011
- Background
Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.
Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.
- Indication
Tetraferric tricitrate decahydrate is indicated to control serum phosphorous in adults with chronic kidney disease who require dialysis. Tetraferric tricitrate decahydrate is also indicated to treat iron deficiency anemia in adults with chronic kidney disease who are not on dialysis.
- Associated Conditions
- Hyperphosphataemia, Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Ferric Citrate and Chronic Kidney Disease in Children
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 160
- Registration Number
- NCT04741646
- Locations
- 🇨🇦
SickKids, Toronto, Ontario, Canada
🇺🇸Cohen's Childrens, New York, New York, United States
🇺🇸Duke, Durham, North Carolina, United States
Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT04649411
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT04543812
- Locations
- 🇨🇳
Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04523727
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of California, San Francisco (UCSF) - Department of Nephrology, San Francisco, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT03984760
- Locations
- 🇨🇳
Meihekou Central Hospital, Meihekou, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, China
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT03256838
- Locations
- 🇨🇳
Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 55
- Registration Number
- NCT03079869
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Ferric Citrate in ESRD Pilot Project
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Sreedhar Mandayam
- Target Recruit Count
- 30
- Registration Number
- NCT03055598
- Locations
- 🇺🇸
US Renal Care- Scott Street, Houston, Texas, United States
🇺🇸Harris Health System - Riverside Dialysis Center, Houston, Texas, United States
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 60
- Registration Number
- NCT02888171
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
- Conditions
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Winthrop University Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT02661295
- Locations
- 🇺🇸
Winthrop University Hospital, Mineola, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.